Skip to main content
University of Michigan Innovation Partnerships
University of Michigan Innovation Partnerships

Diagnostic Pipeline

Company Preclinical CLIA 510K PMA Product on Market Condition/Market 
Arctic DX         Macula Risk Macular Degeneration 
Armune   Apifiny       Tumor Specific Non-PSA Blood Test for Prostate Cancer 
Athena Diagnostics         Atlastin (SPG3A) DNA Sequencing Test (#531), Complete Hereditary Spastic Paraplegia Evaluation (#650), Autosomal Dominant HSP Evaluation (#651) Autosomal Dominant Hereditary Spastic Paraplegia 
Athena Diagnostics         NIPA1 (SPG6) DNA Sequencing Test (#532), Complete Hereditary Spastic Paraplegia Evaluation (#650), Autosomal Dominant HSP Evaluation (#651) 
Athena Diagnostics         MR-1 (PNKD) DNA Sequencing Test (#617) Paroxysmal Nonkinesignenic Dyskinesia 
Athena Diagnostics         FIG4 DNA Sequencing Test (#224), Partial CMT Evaluation – Recessive Only (#409), Complete CMT Evaluation (#723) 
Athena Diagnostics         FIG4 DNA Sequencing Test (#224), Complete ALS Evaluation (#704) Amyotrophic Lateral Sclerosis 
Becton Dickinson HandyLab         Microfluidic Diagnostic System *BD MAX™ Nucleic acid and protein diagnostic 
GenomeDX PCATS       Decipher™ Prostate Cancer 
Hologic   TMPRSS2 Gene Fusions       Prostate Cancer 
Janssen Diagnostics       CTC-Endocrine Index COMETI P2   Metastatic Breast Cancer 
Multiple Non Exclusive Licenses         Delta 508 Mutation Cystic Fibrosis 
Novelos (Cellectar)     I-131NM404 / I124NM404     Pet Imaging Agent for Non-Small Cell Lung Cancer and other Solid Tumors 
Ventana     ERG IVD     Prostate Cancer 
ViraCor IBT         Reg3alpha, ST2 biomarkers Graft Versus Host Disease (GVHD)